11.14.2019
|
Viela Bio Reports Third Quarter 2019 Financial Results and Business Highlights
|
10.09.2019
|
Viela Bio Enters Strategic Collaboration with Mitsubishi Tanabe Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases in Japan and Other Asia Regions
|
10.07.2019
|
Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
10.02.2019
|
Viela Bio Announces Pricing of Initial Public Offering
|
9.09.2019
|
Viela Bio Announces Data Presentations at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
|
9.06.2019
|
Viela Bio Announces Publication in The Lancet of Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder
|
8.27.2019
|
Viela Bio Announces U.S. FDA Accepts for Review Inebilizumab Biologics License Application for Neuromyelitis Optica Spectrum Disorder
|
8.19.2019
|
Viela Bio Announces Appointment of Chris Nolet to its Board of Directors
|
7.01.2019
|
Viela Bio Appoints Mitchell Chan as Chief Financial Officer
|
6.17.2019
|
Viela Bio Closes $75 Million Series B Financing
|